Abstract
Herein, we report on the further chemical optimization of the first reported mGlu(7) positive allosteric modulator (PAM), VU6027459. Replacement of the quinoline core by a cinnoline scaffold increased mGlu(7) PAM potency by ∼ 10-fold, and concomitant introduction of a chiral tricyclic motif led to potent mGlu(7) PAMs with enantioselective mGlu receptor selectivity profiles. Of these, VU6046980 emerged as a putative in vivo tool compound with excellent CNS penetration (K(p) = 4.1; K(p,uu) = 0.7) and efficacy in preclinical models. However, either off-target activity at the sigma-1 receptor or activity at a target not elucidated by large ancillary pharmacology panels led to sedation not driven by activation of mGlu(7) (validated in Grm7 knockout mice). Thus, despite a significant advance, a viable mGlu(7) PAM in vivo tool remains elusive.